Linscomb & Williams Inc. maintained its stake in shares of Laboratory Corporation of America Holdings (NYSE:LH) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,188 shares of the medical research company’s stock at the end of the second quarter. Linscomb & Williams Inc.’s holdings in Laboratory Corporation of America Holdings were worth $491,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Regentatlantic Capital LLC increased its position in Laboratory Corporation of America Holdings by 0.5% during the 2nd quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock worth $261,000 after purchasing an additional 8 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in Laboratory Corporation of America Holdings by 0.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 2,411 shares of the medical research company’s stock worth $346,000 after purchasing an additional 15 shares in the last quarter. New Amsterdam Partners LLC NY increased its position in Laboratory Corporation of America Holdings by 0.7% during the 2nd quarter. New Amsterdam Partners LLC NY now owns 3,847 shares of the medical research company’s stock worth $593,000 after purchasing an additional 27 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Laboratory Corporation of America Holdings by 0.8% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 4,143 shares of the medical research company’s stock worth $594,000 after purchasing an additional 31 shares in the last quarter. Finally, Winslow Evans & Crocker Inc. increased its position in Laboratory Corporation of America Holdings by 0.6% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 7,703 shares of the medical research company’s stock worth $1,186,000 after purchasing an additional 49 shares in the last quarter. Institutional investors and hedge funds own 93.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Laboratory Corporation of America Holdings (LH) Holdings Maintained by Linscomb & Williams Inc.” was originally posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/12/laboratory-corporation-of-america-holdings-lh-holdings-maintained-by-linscomb-williams-inc.html.

In other Laboratory Corporation of America Holdings news, insider Lisa J. Uthgenannt sold 5,000 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total value of $800,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider F Samuel Eberts III sold 31,500 shares of Laboratory Corporation of America Holdings stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $155.22, for a total value of $4,889,430.00. Following the completion of the transaction, the insider now directly owns 31,894 shares in the company, valued at $4,950,586.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 222,968 shares of company stock worth $34,980,922. Company insiders own 0.90% of the company’s stock.

A number of research firms recently issued reports on LH. Barclays PLC increased their target price on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, July 27th. ValuEngine downgraded shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. KeyCorp reissued a “hold” rating on shares of Laboratory Corporation of America Holdings in a research report on Tuesday, September 26th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $170.00 target price (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research report on Wednesday, September 13th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Laboratory Corporation of America Holdings currently has a consensus rating of “Buy” and a consensus target price of $166.33.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.47 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. The company had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.47 billion. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.36 EPS.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.